Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.45 |
| ▸ | CTSK | P43235 | 10/20 | 0.44 |
| ▸ | CTSS | P25774 | 3/20 | 0.44 |
| ▸ | CTSL | P07711 | 5/20 | 0.42 |
| ▸ | CTSB | P07858 | 5/20 | 0.42 |
| ▸ | CTSH | P09668 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29068024 | 0.92 | CTSK (0.41) | CPB2CTSKCTSSCTSLCTSB | |
| SCHEMBL19385540 | 0.85 | CTSK (0.43) | CPB2CTSKCTSSCTSLCTSB | |
| SCHEMBL19385603 | 0.83 | CTSK (0.41) | CPB2CTSKCTSSCTSLCTSB | |
| SCHEMBL29068145 | 0.78 | CTSK (0.42) | CPB2CTSKCTSSCTSLCTSB | |
| SCHEMBL29052567 | 0.77 | CPB2 (0.43) | CPB2CTSKCTSSCTSLCTSB | |
| SCHEMBL29271806 | 0.76 | PRKCA (0.37) | MAPT | |
| SCHEMBL28680208 | 0.76 | PRKCA (0.37) | MAPT | |
| SCHEMBL27726431 | 0.74 | CTSK (0.38) | CTSKCTSSCTSLCTSB | |
| SCHEMBL27910718 | 0.74 | CTSK (0.38) | CTSKCTSSCTSLCTSB | |
| SCHEMBL27834093 | 0.74 | CTSK (0.38) | CTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102015662-A | 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of arway diseases | NOVARTIS AG | 2011-04-13 | — | — | CN | disclosed |